Pre-made Blinatumomab benchmark antibody ( Bispecific T-Cell Engager, anti-CD19;CD3E therapeutic antibody, Anti-B4/CVID3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-074-1mg	1mg	Inquiry
GMP-Bios-ab-074-10mg	10mg	Inquiry
GMP-Bios-ab-074-100mg	100mg	Inquiry
GMP-Bios-ab-074-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody
INN Name	Blinatumomab
Target	CD19;CD3E
Format	Bispecific T-Cell Engager
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	na
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2008
Year Recommended	2009
Companies	Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis
Conditions Approved	Precursor B-cell lymphoblastic leukaemia-lymphoma
Conditions Active	Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma;Richter's syndrome;Burkitt's lymphoma
Conditions Discontinued	Chronic lymphocytic leukaemia
Development Tech	BiTE Technology